Jacqualyn Fouse Increases Stake in Agios Pharmaceuticals

Jacqualyn Fouse, a notable figure in Agios Pharmaceuticals, Inc., recently bought 14,950 shares of the company on June 18, 2026. This insider transaction was not part of a pre-planned trading program, highlighting her direct action in increasing her stake. Shares of Agios Pharmaceuticals, listed on NasdaqGS under the ticker AGIO, traded at $35.47 on Wednesday.

Insider Buying and Selling at Agios Pharmaceuticals, Inc.

In addition to Jacqualyn Fouse, other insiders such as David Scadden, Cynthia Smith, Jay Backstrom, and Rahul Ballal also made purchases on June 18, 2026. Scadden acquired 14,950 shares, while Smith bought 2,816 shares. Backstrom and Ballal each added 14,950 shares to their holdings. These transactions were not conducted under a Rule 10b5-1 plan, suggesting a proactive approach by the insiders.

Other Institutional Activity in Agios Pharmaceuticals

Several institutional investors have adjusted their positions in Agios Pharmaceuticals. BlackRock, Inc. increased its holdings by 519,528 shares, bringing its total to 5,754,957 shares valued at approximately $194.7 million, a 9.9% increase. Farallon Capital Management LLC also raised its stake by 524,495 shares, now holding 5,684,000 shares worth about $192.3 million, marking a 10.2% increase. State Street Corp added 256,734 shares, resulting in a total of 3,364,879 shares valued at $113.7 million, reflecting an 8.3% increase. Conversely, Armistice Capital, LLC reduced its stake by 320,000 shares, now holding 2,716,000 shares valued at $91.9 million, a decrease of 10.5%. Erste Asset Management GmbH trimmed its position by 100,000 shares, leaving it with 2,704,900 shares worth $80.1 million, a 3.6% decrease.

Agios Pharmaceuticals, Inc. Stock Up 3.8%

Agios Pharmaceuticals, Inc. has a market capitalization of approximately $2.09 billion. The company is currently not profitable, with a forward P/E ratio of -7.44. Its stock has experienced a 52-week low of $22.24 and a high of $46.00. The 50-day moving average is $29.03, while the 200-day moving average stands at $31.74. The company maintains a strong liquidity position with a current ratio of 14.19 and a quick ratio of 12.80, alongside a low debt-to-equity ratio of 3.22.

Analysts Set New Price Targets

On June 11, 2026, JP Morgan maintained a 'hold' rating on Agios Pharmaceuticals with a price target of $31.00. B of A Securities kept its 'buy' rating with a target of $40.00 as of May 29, 2026. Truist Securities also maintained a 'buy' rating, setting a target price of $36.00 on April 30, 2026. The consensus among analysts is a 'buy' recommendation, with a mean target price of $40.75, based on eight analyst opinions.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focusing on developing medicines in the field of cellular metabolism. The company's flagship product, PYRUKYND (mitapivat), targets hemolytic anemias in adults with pyruvate kinase deficiency. Agios is also advancing treatments for sickle cell disease and thalassemia, and is working on various other therapies targeting metabolic disorders. The company was founded in 2007 and is led by CEO Mr. Brian M. Goff.

Bottom Line

Jacqualyn Fouse's recent purchase of Agios Pharmaceuticals shares highlights continued insider interest in the company. Agios, with its strong pipeline in the biotechnology sector, remains under the watchful eye of institutional investors and analysts. Remember, insider transactions like these are disclosed after they occur, reflecting past actions rather than current intentions.